Skip to main content

Table 13 Assay results for the determination of VPS and SFV in their co-formulated tablet by Method 2

From: Two novel UPLC methods utilizing two different analytical columns and different detection approaches for the simultaneous analysis of velpatasvir and sofosbuvir: application to their co-formulated tablet

Studied drug

Proposed method

Comparison method [11]

Amount taken (ng/mL)

Amount found (ng/mL)

% Found

% Found

Column (A)

Column (B)

Column (A)

Column (B)

Column (A)

Column (B)

SFV Epclusa® tablet (SFV 400 mg/VPS 100 mg)

200.0

200.0

196.900

199.520

98.45

99.76

99.98

400.0

400.0

389.760

394.920

97.44

98.73

98.93

600.0

600.0

596.760

589.080

99.46

98.18

100.83

Mean

    

98.45

98.89

100.85

 ±SD

    

1.01

0.80

0.95

t-test

    

1.83

1.42

(2.78)*

F-test

    

1.12

1.41

(19)*

VPS

50.0

50.0

48.810

49.955

97.62

99.91

102.45

Epclusa® tablet (SFV 400 mg/VPS 100 mg)

100.0

100.0

98.000

98.040

98.00

98.04

101.78

150.0

150.0

148.665

148.185

99.11

98.79

98.91

Mean

    

98.24

98.91

101.05

 ±SD

    

0.77

0.94

1.88

t-test

    

2.39

1.76

(2.78)*

F-test

    

5.89

3.99

(19.0)*

  1. Each result is the average of three separate determinations
  2. * The figures between parentheses are the tabulated t and F values at P = 0.05 [17]